Literature DB >> 22228175

Quantitative RT-PCR analysis of PSA and prostate-specific membrane antigen mRNA to detect circulating tumor cells improves recurrence-free survival nomogram prediction after radical prostatectomy.

David R Yates1, Morgan Rouprêt, Sarah J Drouin, Eva Comperat, Sylvie Ricci, Roger Lacave, Philippe Sèbe, Geraldine Cancel-Tassin, Marc-Olivier Bitker, Olivier Cussenot.   

Abstract

BACKGROUND: Circulating tumor cell (CTC) analysis is a potential new biomarker in prostate cancer. We hypothesize that quantitative detection of CTCs in patients pre- and post-radical prostatectomy (RP) using quantitative TaqMan® fluorogenic RT-PCR will improve the accuracy of the Kattan nomogram to predict the probability of recurrence-free survival (RFS) post-RP.
METHODS: Ninty-two patients who underwent RP between 2004 and 2009 had venous blood samples taken pre- (Day - 1) and post-operatively (Day + 7). We performed quantitative Taqman® RT-PCR to detect circulating prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) mRNA. We calculated both the logarithmic ratio of Day + 7/Day - 1 for PSA (PSAr) and PSMA (PSMAr) expression (log(Day+7/Day-1) ) and the Kattan nomogram predicted probability of disease recurrence for each patient. We then analyzed how the AUC-ROC analysis for the Kattan nomogram prediction alone (K) compared to the addition of the PSAr and PSMAr in predicting 5-year RFS.
RESULTS: The mean age (years), PSA (ng/ml), and follow-up (mo) was 65.1, 9.13, and 72, respectively. The AUCs for K, PSAr + K, and PSMAr + K were 0.752 (95%CI 0.620-0.860), 0.830 (95%CI 0.740-0.911), and 0.837 (95%CI 0.613-0.923), respectively (P = 0.03). The Kattan 5-year PSA RFS was 75%. The actual 5-year PSA RFS survival rate was 77%.
CONCLUSIONS: Data from modern quantitative RT-PCR to detect circulating prostate-derived PSA and PSM mRNA pre- and post-RP improves the accuracy of the Kattan nomogram to predict biochemical recurrence.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228175     DOI: 10.1002/pros.22488

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  20 in total

Review 1.  Isolated, disseminated and circulating tumour cells in prostate cancer.

Authors:  David Schilling; Tilman Todenhöfer; Jörg Hennenlotter; Christian Schwentner; Tanja Fehm; Arnulf Stenzl
Journal:  Nat Rev Urol       Date:  2012-07-10       Impact factor: 14.432

Review 2.  Gene expression profiling and DNA methylation analyses of CTCs.

Authors:  Evi S Lianidou
Journal:  Mol Oncol       Date:  2016-02-05       Impact factor: 6.603

Review 3.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

Review 4.  Research landscape of liquid biopsies in prostate cancer.

Authors:  Esther Campos-Fernández; Letícia S Barcelos; Aline Gomes de Souza; Luiz R Goulart; Vivian Alonso-Goulart
Journal:  Am J Cancer Res       Date:  2019-07-01       Impact factor: 6.166

5.  Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.

Authors:  Julie L Kasperzyk; Stephen P Finn; Richard Flavin; Michelangelo Fiorentino; Rosina Lis; Whitney K Hendrickson; Steven K Clinton; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-15       Impact factor: 4.254

Review 6.  Clinical utility of circulating tumor cells: an update.

Authors:  Antoine Vasseur; Nicolas Kiavue; François-Clément Bidard; Jean-Yves Pierga; Luc Cabel
Journal:  Mol Oncol       Date:  2020-12-25       Impact factor: 6.603

7.  Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.

Authors:  Fengyi Mao; Yifan Kong; Jinghui Liu; Xiongjian Rao; Chaohao Li; Kristine Donahue; Yanquan Zhang; Katelyn Jones; Qiongsi Zhang; Wei Xu; Xiaoqi Liu
Journal:  Prostate       Date:  2022-03-24       Impact factor: 4.104

8.  Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen.

Authors:  Justin P Dassie; Luiza I Hernandez; Gregory S Thomas; Matthew E Long; William M Rockey; Craig A Howell; Yani Chen; Frank J Hernandez; Xiu Ying Liu; Mary E Wilson; Lee-Ann Allen; Daniel A Vaena; David K Meyerholz; Paloma H Giangrande
Journal:  Mol Ther       Date:  2014-06-23       Impact factor: 11.454

9.  Isolation and characterization of circulating tumor cells in prostate cancer.

Authors:  Elan Diamond; Guang Yu Lee; Naveed H Akhtar; Brian J Kirby; Paraskevi Giannakakou; Scott T Tagawa; David M Nanus
Journal:  Front Oncol       Date:  2012-10-11       Impact factor: 6.244

10.  The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood.

Authors:  Irvin M Modlin; Ignat Drozdov; Mark Kidd
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.